For Patients For Caregivers For Medical Professionals

HELPLINE 1-800-465-4837
Mon-Fri 9am – 7pm

Loading Events

« All Events

  • This event has passed.

3/26 Medical Professional Webinar: Hepatocellular Carcinoma and HCV Cure with DAAs: Update and Current Challenges

March 26, 2019 @ 7:00 pm - 8:00 pm
Pro Education Webinar

Hepatocellular Carcinoma and HCV Cure with DAAs: Update and Current Challenges

This hour-long webinar presentation will address the confusion about the association between HCV cure with DAAs and HCC risk, and will be followed by a question-and-answer session.  This activity is intended for clinicians engaged in the care of patients with Hepatitis C and hepatocellular carcinoma. (Professional credits will be offered.)

Webinar is on Tuesday, 3/26, and will run from 7pm ET until 8pm ET.

Speaker: Hashem B. El-Serag, M.D., M.P.H.

Margaret M. and Albert B. Alkek Professor and Chair

Department of Medicine

Baylor College of Medicine

Click Here to Register for the Presentation!

CME/CE/MOC Credits

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and American Liver Foundation.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     This activity is approved for ABIM Maintenance of Certification Part 2 credit.


Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hours.


There is no fee for this educational activity.

Educational Objectives

·       Recognize that treatment of HCV with DAAs can reduce cancer risk.

·       Discuss with HCV-positive patients their risk of HCC and explain the benefits of DAA treatment in reducing risk.

·       Adhere to HCC surveillance guidelines for at-risk patients.


March 26, 2019
7:00 pm - 8:00 pm
Event Categories:
, ,
Event Tags:
, , , , , , ,